MARKET

PTCHF

PTCHF

Puretech Health
OTCPK
1.560
NaN%
Closed 09:30 11/18 EST
OPEN
--
PREV CLOSE
1.560
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.850
52 WEEK LOW
1.480
MARKET CAP
382.48M
P/E (TTM)
1418.18
1D
5D
1M
3M
1Y
5Y
1D
PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category
Barchart · 10/30 02:00
PureTech Founded Entity Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
Barchart · 10/29 06:01
Celea Therapeutics Appoints Paul Audhya, MD, MBA, as Chief Medical Officer
Barchart · 10/29 06:00
PureTech Founded Entity Seaport Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial Evaluating GlyphAgo™ in Patients with Generalized Anxiety Disorder and Sleep Disturbance
Barchart · 10/07 12:00
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
Barchart · 09/21 01:00
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Barchart · 09/09 12:13
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
Barchart · 08/25 06:05
PureTech Health: Results of Annual General Meeting
Barchart · 06/10 12:14
More
About PTCHF
PureTech Health plc is a clinical-stage company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

Webull offers Puretech Health PLC stock information, including OTCPK: PTCHF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PTCHF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PTCHF stock methods without spending real money on the virtual paper trading platform.